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A B S T R A C T
Purpose
Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We
sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophos-
phamide (AC), when each was administered for four or six cycles of therapy, and whether it
offered less toxicity.
Patients and Methods
Patients with operable breast cancer with 0 to 3 positive nodes were enrolled onto the study to
address the noninferiority of single-agent T to AC, defined as the one-sided 95% upper-bound CI
(UCB) of hazard ratio (HR) of T versus AC less than 1.30 for the primary end point of relapse-free
survival (RFS). As a 2  2 factorial design, duration of therapy was also addressed and was
previously reported.
Results
With 3,871 patients enrolled onto the trial, a median follow-up period of 6.1 years, and 437 RFS
events, we achieved an HR of 1.26 (one sided 95% UCB, 1.48; favoring AC does not allow a
conclusion of noninferiority of T with AC; UCB  1.3). With 266 patient deaths, the HR for overall
survival (OS) was 1.27 favoring AC (UCB, 1.56). The estimated absolute advantage of AC at 5 years
is 3% for RFS (91 v 88%) and 1% for OS (95 v 94%). All nine treatment-related deaths were
patients receiving AC and are included in the analyses of both RFS and OS. Hematologic toxicity
was more common in patients treated with AC, and neuropathy was more common in patients
treated with T.
Conclusion
This trial did not show noninferiority of T to AC, a conclusion that is unlikely to change with
additional events and follow-up. T was less toxic than AC.
J Clin Oncol 32:2311-2317. © 2014 by American Society of Clinical Oncology
INTRODUCTION
A large proportion of patients with breast cancer
now show symptoms of early-stage disease and,
with modern surgical, radiation, and systemic
treatments, their long-term survival rates have
continually improved. In the United States, 80%
of patients with breast cancer survive 10 years or
longer. Adjuvant chemotherapy has played a ma-
jor role in improving outcomes, and there has
been a continual effort to identify regimens with
higher relapse-free (RFS) and overall survival
(OS) rates.1 As long-term outcomes have im-
proved and issues of survivorship have gained
more attention, short- and long-term toxicity
have become increasingly important.
National Surgical Adjuvant Breast and Bowel
Project trial B-15 showed that the four cycles of
cyclophosphamide and doxorubicin (AC) was
equivalent to six cycles of cyclophosphamide, meth-
otrexate, and fluorouracil and established AC as a
standard adjuvant regimen for breast cancer.2 More
recently, taxanes have been added to AC regimens or
substituted for one of the agents. Some studies have
investigated four cycles of therapy while others have
used six cycles.3-7
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Cancer and Leukemia Group B (CALGB) trial 40101 is a North
American Breast Intergroup trial that used a 2  2 factorial design to
test the noninferiority of single-agent paclitaxel (T) with AC and the
superiority of six cycles of therapy over four cycles. Interest in testing
the noninferiority of T with AC was based on data from patients with
locally advanced or metastatic disease, in which single-agent taxanes
seemed to have relatively equivalent efficacy compared with combina-
tion chemotherapy built on the AC backbone.8,9 The decision to test
four cycles versus six cycles of therapy was based on the use of four or
six cycles in previous studies without evidence to support one dura-
tion over the other.3-7 The results of the duration of therapy question
have been previously published and have shown no difference in
outcome for six cycles versus four cycles of therapy.10 Our article
outlines the results from the T versus AC component of the study.
PATIENTS AND METHODS
CALGB 40101 (NCT00041119, supported by the National Cancer Institute
and CALGB) was initiated in 2002 as a 2  2 factorial design to test as adjuvant
chemotherapy the noninferiority of T versus AC and the superiority of longer
versus shorter therapy, initially for women with node-negative disease and
eventually for women with 1 to 3 positive nodes as well. When the protocol was
originally written, the comparison was termed “equivalence” and is stated as
such in the protocol, but current terminology is “noninferiority” and this term
is used in our article.
Eligibility criteria included women older than 18 years old who had
operable breast cancer and whose treating physicians deemed they needed
adjuvant chemotherapy based on their tumor size, grade, hormone receptor
status, HER2/neu status, lymphovascular involvement, and potentially other
factors. The protocol provided general guidelines for tumor characteristics
that might warrant consideration of adjuvant chemotherapy, however, the
final decision was left to the treating physician. Protocol guidelines suggested
that for patients with node-negative and hormone receptor–positive disease,
patients with tumors  1 cm in size should be considered for chemotherapy;
for patients with hormone receptor-negative disease, patients with tumors of
any size might be considered for chemotherapy. For patients with 1 to 3
positive nodes, tumors of any size and any hormone receptor status should be
considered for chemotherapy. This was intended to replicate community-
standard nonprotocol decision-making regarding the need for chemotherapy
in these patients. Estrogen receptor (ER), progesterone receptor (PgR) and
HER2 testing was performed by the local institution without central review.
Patients could not have locally advanced disease, such as skin involvement,
chest wall involvement, or inflammatory cancer. Patients were required to
have adequate liver, renal, and hematologic function. When the study was
activated in 2002, only women with node-negative disease were eligible; in
2005, study eligibility was expanded to include women with one to three
positive axillary nodes. The rationale for this modification was two-fold; the
protocol-specified regimens were appropriate for this group of patients, and
accrual would be increased. Sentinel node assessment was acceptable for pa-
tients with negative sentinel nodes. If sentinel node(s) were positive, a comple-
tion dissection was required, with at least six total nodes (sentinel nodes plus
dissection) required for evaluation. Tumor margins were required to be neg-
ative for patients undergoing both breast-conserving surgery and mastectomy.
In February 2008, with a total enrollment of 3,171 patients, the six-cycle
study arms were closed because of slowing accrual, and randomization was
henceforth restricted to two study arms: four cycles of AC and four cycles of T.
The trial was permanently closed to accrual in July 2010 because of continued
slowing accrual, with a final total accrual of 3,871 patients, which was short of
the planned target of 4,646 patients.
At trial inception, AC was administered once every 3 weeks for four
cycles (12 weeks) or six cycles (18 weeks) and T was administered weekly for 12
or 18 weeks (3 weeks of T was equivalent to one cycle). During this initial
period of the trial, 571 patients were accrued. In 2003, when CALGB 9741
showed superiority of dose-dense therapy administered every 2 weeks versus
every 3 weeks,11 CALGB 40101 was amended so AC and T were administered
every 2 weeks for four or six cycles. AC was administered as doxorubicin 60
mg/m2 intravenously, and cyclophosphamide as 600 mg/m2 IV. Paclitaxel was
administered as 80 mg/m2 IV when given weekly, and 175 mg/m2 intrave-
nously when given once every 2 weeks.. WBC growth factor support (either
filgrastim or pegfilgrastim) was recommended for patients receiving dose-
dense therapy.
Hormone therapy (tamoxifen for any patient or aromatase inhibitors in
postmenopausal women) was recommended for patients with hormone
receptor–positive tumors. After 2005, trastuzumab was permitted for women
with HER2-positive tumors.
Radiation therapy was required for women undergoing breast-
conserving surgery, though the type of radiation (eg, whole breast or partial
breast) was determined by the treating physicians. Postmastectomy radiation
could be given at the discretion of the treating physicians.
Patients had to have been enrolled and randomly assigned onto the study
within 84 days of their last breast surgery, and treatment had to be initiated
within 7 days of random assignment. Randomization used a permuted block
design with fixed block size of 12 allocated patients with equal probability to
one of the four possible treatment arms. Randomization was stratified by
menopausal status, hormone receptor status, and, after October 2005,
HER2 status.
After completion of protocol chemotherapy, patients were asked to
receive follow-up every 6 months for the first 2 years and annually thereafter
for 15 years after enrollment.
Primary objectives of the study were to test the noninferiority of T
compared with AC and the superiority of six cycles of therapy over four cycles
of therapy, both in regard to RFS. Secondary objectives included the same
comparisons for OS. Other secondary objectives included the evaluation of
toxicities for patients receiving AC and T for six cycles and four cycles of
therapy and the induction of menopause (defined as  12 months without
menstruation) in premenopausal women by treatment arm.
Each patient gave written approval on a protocol-specific, institutional
review board–approved consent form.
The primary study end point was RFS as defined by STEEP (Stan-
dardized Definitions of Efficacy Endpoints) criteria, measured from study
entry until local recurrence, distant relapse, or death without relapse,
whichever occurred first.12 All new primary sites, regardless of location,
were considered adverse events and not events in RFS. Surviving patients
who were relapse-free were censored at the date of last clinical assessment.
The secondary end point of OS was measured from study entry until death
from any cause; surviving patients were censored at the date of last contact.
The study was designed with 89% power (one-sided alpha, .05) to test the
noninferiority of T with AC. Noninferiority was defined as the 5-year RFS of T
being not less than 84.7%, assuming a 5-year RFS of 88% for AC. This
corresponds to a hazard ratio (HR) of T:AC of 1.3. The study’s target accrual
was 4,646 patients, with 567 RFS events expected at the final analysis.
The test of noninferiority used an HR of T:AC and the one-sided 95%
upper bound CI obtained from a univariable proportional hazards model
stratified by the study stratifiers. An upper bound of less than 1.3 was evidence
to conclude that T was noninferior to AC.
The primary analysis used proportional hazards modeling that adjusted
for tumor size, number of involved lymph nodes, hormone receptor status
(either ER- or PgR-positive status v -negative), and menopausal status.13
Except for the agent, the statistical significance of each variable included in the
models was assessed using the corresponding Wald 2 statistics. HRs and their
95% CIs were obtained from multivariable proportional hazards models. The
relationship between agent and treatment length regarding RFS and OS was
described with proportional hazards models using an interaction term con-
structed as the cross-product of the agent and length. To address the impact of
modifying treatment duration (from every 3 weeks to every 2 weeks) and nodal
involvement (from zero to 0 to 3) on clinical outcome, primary analyses were
repeated in an ad hoc manner on the resulting subgroups. Because the study
was not powered to assess interactions or subgroup analyses, any such refer-
ences are considered descriptive and presented without significance levels.
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RFS and OS distributions were estimated using the Kaplan-Meier prod-
uct limit technique.14 Log-rank tests compared distributions of two or more
groups.15 95% CIs of time-to-event variables used the method of Hosmer
and Lemeshow.16
Predictive probability was calculated using Bayesian methods that as-
sumed an exponential time-to-event distribution with independent and non-
informative prior distributions about the parameters.17 Efficacy analyses used
an intention-to-treat approach. Adverse events were reported using National
Cancer Institute Common Toxicity Criteria version 4.0.18 Additional statisti-
cal information is available in the Appendix (online-only).
RESULTS
A total of 3,871 patients were enrolled onto the study between 2002
and 2010 (Fig 1). Patient characteristics and baseline clinicopathologic
variables are listed in Table 1; these were well balanced between the AC
and T arms. Of note is that 90% of patients had node-negative disease
and 68% of patients had hormone-receptor–positive disease. Only
48% of patients had their tumors assayed for HER2, and, among those
assayed, 84% were negative.
At a median follow-up period of 6.1 years, there were 437 RFS
events; 192 events were in the AC arms and 245 were in the T arms.
The HR from the stratified proportional hazards model was 1.26
(UCB, 1.48) favoring AC. Because the upper limit of the confidence
interval exceeds an HR of 1.3, the upper boundary that would be
required to conclude noninferiority, we cannot conclude noninferior-
ity of T compared with AC. A total of 266 patients died; 116 patients in
the AC arms, and 150 patients in the T arms. The HR from a corre-
sponding stratified model was 1.27 (UCB, 1.56), also favoring AC, and
therefore noninferiority of T compared with AC could not be shown
since the upper limit of the CI was above 1.3. Based on the current
data, with 437 RFS events, the Bayesian predictive probability of con-
cluding noninferiority of T compared with AC if the trial had achieved
567 RFS events is less than 5%. Ad hoc analyses to examine the impact
on clinical outcome of changing treatment scheduling (from every 3
weeks to every 2 weeks) and nodal involvement (from zero to zero to
three) gave results in keeping with those of the primary analyses that
included the entire study group (data not shown).
Results of multivariable proportional hazards modeling also in-
dicated that T was not shown to be noninferior to AC for either RFS or
OS, after adjusting for the effects of tumor size, number of positive
nodes, hormone receptor status, or menopausal status (Appendix
Table A1).
RFS and OS distributions are illustrated in Figure 2. The 5-year
RFS was 91% for patients treated with AC and 88% for those treated
with T. OS at 5 years was 95% for patients treated with AC and 94% for
those treated with T. Also shown in Figure 2 is RFS by arm within
hormone receptor status (positive or negative). T had a numerically
poorer outcome than AC regardless of hormone receptor status. Fig-
ure 3 shows RFS for all four arms and indicates a lack of interaction
between regimen and duration. These findings are consistent across
duration and regimen questions; that is, six cycles of therapy is not
superior to four cycles for patients treated with AC or T and T is not
equivalent to AC regardless of treatment duration.
A total of 3,754 patients were evaluable for toxicity that occurred
during treatment. As expected, the incidence of any grade 3 or higher
hematologic toxicity was considerably higher in the AC arms com-
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Fig 1. CONSORT diagram. Randomized
controlled trial: patients registered, treatment-
arm assignments, and exclusions. Cyclo-
phosphamide and doxorubicin (AC) was ad-
ministered as noted as doxorubicin 60
mg/m2 and cyclophosphamide 600 mg/m2
given every 2 or 3 weeks for four or six
cycles. T (paclitaxel) was administered as 80
mg/m2 when given weekly for 12 or 18
weeks (3 weeks equaling one cycle) or as
175 mg/m2 when administered every 2
weeks for four to six cycles.
Table 1. Patient Characteristics by Regimen
Characteristic
Percent of Patients by Regimen
AC (n  1,931) T (n  1,940)
All Regimens
(n  3,871)
Age  50 years 61 62 61
Non-white race 16 17 16
Premenopausal 40 39 40
Node-negative 89 90 90
Tumor size  2 cm 66 63 65
HR-positive tumors 68 68 68
HER2-negative tumors 85 84 84
High grade 46 45 46
Mastectomy 35 35 35
Abbreviations: AC, doxorubicin/cyclophosphamide; HER2, human epidermal
growth factor receptor 2; HR, hormone receptor; T, paclitaxel.
Tumoral HER-2 was measured in 48% of patients. Table entries are based
upon patients with HER-2 data.
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Also as expected, neuropathy was the most frequent nonhema-
tologic adverse event and was more common in the T than the AC
arms (grade 3 events in the six-cycle T arm, 12%; grade 3 events in the
four-cycle T arm, 5%). Grade 4 neurotoxicity was rare, occurring in
less than 1% of patients. Incidence of other nonhematologic toxicities
was not more than 3%. Selected grade 3 and 4 toxicities are listed in
Table 2. Cardiac toxicity was infrequent in all of the treatment arms
(Appendix Table A2). Two cardiac deaths (both on AC arms) were
attributed to protocol treatment. One patient, who was randomly
assigned to the AC  4 arm under the every-3-week schedule, died of
a myocardial infarction 96 days after enrollment. The other patient,
who was randomly assigned to the AC  6 arm, died shortly after
completing protocol therapy, 127 days after enrollment, as a result of
left-ventricular dysfunction.
Seven patients, all on the AC arms, developed acute myelogenous
leukemia or myelodysplastic syndrome between 11 and 34 months
after enrollment onto the study. All seven patients died, and their
deaths are considered to be related to treatment.
Causes of death are listed in Table 3. In total, 266 patients died;
116 patients who were receiving AC and 150 who were receiving T. Of
these, 147 patients’ deaths were known to be related to breast cancer
(AC, 60 deaths; T, 87 deaths). The cause of death for the remaining 110
patients was not related to breast cancer or treatment, was uncon-
firmed breast cancer, or was unknown.
DISCUSSION
CALGB 40101 was designed to test the potential noninferiority of T
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Fig 2. (A) relapse-free survival (RFS) for all patients (hazard ratio [HR] 1.26; 95% CI, 1.05 to 1.53) favoring doxorubicin and cyclophosphamide (AC); (B) overall survival (OS) for all





























Fig 3. Relapse-free survival by treatment arm. Doxorubicin and cyclophosphamide
(AC) was administered as noted as doxorubicin 60 mg/m2 and cyclophosphamide 600
mg/m2 given every 2 or 3 weeks for four or six cycles. Paclitaxel (T) was administered as
80 mg/m2 when given weekly for 12 or 18 weeks (3 weeks equaling one cycle) or as 175
mg/m2 when administered every 2 weeks for four or six cycles.
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would provide women with good-prognosis primary breast cancer a
less toxic, equally efficacious option. Because we were not able to
demonstrate noninferiority for either RFS or OS, single-agent T can-
not be recommended as a standard regimen for women with primary
breast cancer and zero to three positive axillary nodes. In addition,
there was no subgroup in which clinical outcome from T was nonin-
ferior to that of AC. There was also no differential effect of agent by
duration of therapy (four v six cycles).
The majority of patients of our study received dose-dense AC
and dose-dense T. The decision to convert to this schedule was
based on the publication of CALGB 9741, which demonstrated that
dose-dense AC followed by T was superior to AC followed by T,
given every 3 weeks.11 Despite the unexpected protocol modifica-
tions to schedule and eligibility after accrual had begun, explor-
atory ad hoc comparisons by cycle length of every 3 weeks versus
every 2 weeks and by nodal involvement of node-negative versus
either node-negative or node-positive disease gave results in keep-
ing with those of the overall analyses. Thus, our conclusions are the
same regardless of modifications to treatment schedule and
nodal status.
Multiagent chemotherapy became a standard of antineoplas-
tic therapy since regimens such as mustargen, vincristine, procar-
bazine, and prednisone (MOPP) for Hodgkin’s lymphoma and
complex regimens for acute lymphoblastic leukemia were shown
to be curative. Based on these findings and principles, adjuvant
regimens for the treatment of localized breast cancer have exclu-
sively been multiagent in nature. However, in the setting of meta-
static breast cancer, single-agent chemotherapy has in some studies
been associated with equal survival rates when compared with
intensive multiagent regimens. Our study would suggest that
single-agent taxane as adjuvant therapy is not optimal therapy for
these women.
The precise role of taxanes in adjuvant breast cancer regi-
mens remains unclear. Though regimens such as AC followed
by a taxane have often been used in women with high-risk primary
breast cancer, AC alone has remained a standard regimen for many
better-risk patients with primary breast cancer. Eastern Coopera-
tive Oncology Group trial 2197 compared four cycles of AC as
the standard of care, with four cycles of doxorubicin and do-
cetaxel in women with zero to three positive nodes, and found
that there was no survival advantage to the combination of doxo-
rubicin and docetaxel over AC, and that there was no survival
advantage to the combination of doxorubicin and docetaxel (AT)
over AC, and that AT was more toxic.5 Of note is that 66% of these
patients had node-negative disease, compared with 90% in our
study. Docetaxel and cyclophosphamide has been widely adopted
in practice based on a modest size, single trial that demonstrated
superiority for this regimen over AC in women with node-negative
and node-positive disease.6 Docetaxel and cyclophosphamide is
also associated with substantial toxicity and our hope had been that
single-agent taxane therapy might be noninferior and less toxic.
Given the results of our trial, AC (which had a 5-year RFS of 91%
and a 5-year OS of 95%) but not single-agent T remains among the
reasonable options for patients with lower-risk disease based on
tumor volume and tumor characteristics. The use of adjuvant
chemotherapy is evolving and chemotherapy use is increasingly
based on molecular features of the tumor (such as multigene
predictionassays)todeterminewhichpatientsshouldreceivechem-
otherapy. Molecular characteristics of the tumor may similarly
become helpful in selecting specific chemotherapy regimens.
In summary, we could not conclude noninferiority of single-
agent T compared with AC to treat women with zero to three positive
axillary nodes in regard to either relapse-free or overall survival. AC
was more toxic, and all treatment-related deaths occurred in patients
Table 2. Selected Grade 3 and 4 Adverse Events During Protocol Therapy by Treatment Arm
Adverse Event
% of Events by Treatment Arm
AC  4 (n  1,107) AC  6 (n  766) T  4 (n  1,119) T  6 (n  762)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Hemoglobin 4  1 6 1  1 0 1  1
Neutropenia 8 18 10 23 2 1 2 1
Febrile neutropenia 5  1 6  1  1 0 0 0
Thrombocytopenia 1  1 3 1  1 0 0 0
Neuropathy (sensory and/or motor)  1 0  1 0 5  1 12  1
Diarrhea 1  1 2 0 1 0 1 0
Vomiting 3 0 3 0  1  1 0 0
Fatigue 3  1 6  1 1  1 3 0
Arthralgia  1 0  1 0 2 0 2  1
NOTE. Doxorubicin and cyclophosphamide (AC) was administered every 2 or 3 weeks as noted as doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for
four or six cycles. T (paclitaxel) was administered as 80 mg/m2 when given weekly for 12 or 18 weeks (3 weeks equaling one cycle) or as 175 mg/m2 when
administered every 2 weeks for four or six cycles.
Table 3. Causes of Death by Treatment Regimen
Cause of Death
No. of Patients Who Died Within Regimen
AC (n  1,931) T (n  1,940) Total (n  3,871)
Breast cancer 60 87 147
Treatment-related death 9 0 9
AML/MDS 7 0 7
Cardiotoxicity 2 0 2
Other 47 63 110
Total No. of deaths 116 150 266
Abbreviations: AC, doxorubicin/cyclophosphamide; AML, acute myeloge-
nous leukemia; MDS, myelodysplastic syndrome; T, paclitaxel.
Single-Agent Paclitaxel v AC As Adjuvant Therapy in Breast Cancer
www.jco.org © 2014 by American Society of Clinical Oncology 2315
treated with AC. These findings support AC as an option as standard
of care, whereas our previous findings support four cycles of therapy as
a standard duration of therapy for these patients.
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GLOSSARY TERMS
estrogen receptor (ER): ligand-activated nuclear proteins,
belonging to the class of nuclear receptors, present in many
breast cancer cells that are important in the progression of
hormone-dependent cancers. After binding, the receptor-ligand
complex activates gene transcription. There are two types of es-
trogen receptors (ER and ER). ER is one of the most impor-
tant proteins controlling breast cancer function. ER is present
in much lower levels in breast cancer, and its function is uncer-
tain. Estrogen receptor status guides therapeutic decisions in
breast cancer.
HER2/neu (human epidermal growth factor
receptor 2): also called ErbB2. HER2/neu belongs to the epi-
dermal growth factor receptor (EGFR) family and is overex-
pressed in several solid tumors. Like EGFR, it is a tyrosine kinase
receptor whose activation leads to proliferative signals within the
cells. On activation, the human epidermal growth factor family of
receptors are known to form homodimers and heterodimers,
each with a distinct signaling activity. Because HER2 is the pre-
ferred dimerization partner when heterodimers are formed, it is
important for signaling through ligands specific for any members
of the family. It is typically overexpressed in several epithelial
tumors.
overall survival: the duration between random assignment and
death.
progesterone receptor (PgR): nuclear proteins that are activated
by the hormone progesterone in breast cancer cells that are
hormone-dependent.
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Appendix
Per National Cancer Institute policy, our study was monitored every 6 months by an independent data and safety monitoring board
(DSMB), beginning in November 2002. Preplanned interim analyses of noninferiority used the stratified univariable proportional hazards
model described above. The Lans-Demets spending function was used in interim analyses and assumed an overall one-side significance
level of 0.05 (DeMets et al: Stat Med 13:1341-1352, 1994). The first formal interim analysis, scheduled at 10% of the total expected events,
was conducted in June 2006. Thereafter, interim analyses were conducted once every two years until June 2008. In June 2010, the DSMB
released the results for the four- versus six-cycle comparison. In December 2012, the DSMB released the results of the doxorubicin and
cyclophosphamide versus paclitaxel noninferiority comparison.
Study data were collected by Cancer and Leukemia Group B (CALGB; Alliance) Statistics and Data Center and were stored in the
CALGB (Alliance) database. Data quality was ensured by review of data by the Statistics and Data Center and by the study chairperson per
group policies. All analyses were conducted by CALGB (Alliance) statisticians. The data cutoff for this report was December 2012.




RFS (11% of events) OS (7% of events)
HR 95% CI P HR 95% CI P
Agent T:AC 1.25 1.47 (UCB) N/A† 1.25 (UCB) 1.53 N/A†
Tumor size, cm 2:1.5 1.15 1.10 to 1.21  .0001 1.19 1.12 to 1.27  .0001
No. of positive nodes 2:0 1.21 0.81 to 1.81 .35 1.54 0.94 to 2.51 .089
Hormone receptor Neg:pos 1.74 1.44 to 2.11  .0001 2.22 1.74 to 2.83  .0001
Menopausal status Post:pre 1.15 0.95 to 1.39 .17 1.73 1.33 to 2.26  .0001
Abbreviations: AC, doxorubicin/cyclophosphamide; HR, hazard ratio; N/A, not applicable; Neg, negative; OS, overall survival; pos, positive; post, postmenopausal;
pre, premenopausal; RFS, relapse-free survival; T, paclitaxel; UCB, upper confidence bound.
One-sided 95% CI.
†P value is not applicable. Noninferiority is tested by UCB ( 1.3 for both RFS and OS models).
Table A2. Grade  3 Cardiotoxicity During Protocol Therapy
Adverse Event
No. of Events by Treatment Arm

























LV systolic dysfunction 2 0 0 3 2 1 0 0 0 1 1 0
Restrictive cardiomyopathy 0 0 0 1 0 0 0 0 0 0 0 0
General cardiac 0 0 1 0 0 0 1 0 0 1 0 0
NOTE. Doxorubicin and cyclophosphamide (AC) was administered every 2 or 3 weeks as noted as doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for
four or six cycles. T (paclitaxel) was administered as 80 mg/m2 when given weekly for 12 or 18 weeks (3 weeks equaling one cycle) or as 175 mg/m2 when
administered every 2 weeks for four or six cycles.
Abbreviation: LV, left ventricular.
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